Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study
Keep reading
Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018
